Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
We assessed the avidity maturation process elicited by human immunization with alum-adsorbed HBsAg alone or with a novel adjuvant containing CpG motifs (CpG 7909). Mean avidity indexes and distribution of low- and high-avidity anti-HBs indicated that avidity maturation essentially takes place late after priming. CpG 7909 markedly enhanced this affinity maturation process, increasing the pool of high-avidity antibodies. The influence of CpG 7909 was antigen-specific, isotype-specific and distinct from the influence on anti-HBs production, as avidity did not correlate with anti-HBs IgG titers. This is the first demonstration that a novel human adjuvant may induce antibodies with higher antigen-binding affinity.
Siegrist
Claire-Anne
CA
Department of Pediatrics, Center for Vaccinology and Neonatal Immunology, University of Geneva, C.M.U., 1 rue Michel-Servet, 1211 Geneva 4, Switzerland. Claire-Anne.Siegrist@medecine.unige.ch
Pihlgren
Maria
M
Tougne
Chantal
C
Efler
Sue M
SM
Morris
Mary Lou
ML
AlAdhami
Mohammed J
MJ
Cameron
D William
DW
Cooper
Curtis L
CL
Heathcote
Jenny
J
Davis
Heather L
HL
Lambert
Paul-Henri
PH
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000915:Antibody Affinity; D000918:Antibody Specificity / Q000276:immunology; D001402:B-Lymphocytes; D005260:Female; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007074:Immunoglobulin G; D009838:Oligodeoxyribonucleotides; C483020:ProMune